Cardan Capital Partners LLC acquired a new stake in shares of Cambrex Co. (NYSE:CBM) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 30,038 shares of the biotechnology company’s stock, valued at approximately $2,055,000. Cardan Capital Partners LLC owned 0.09% of Cambrex at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of CBM. Janus Henderson Group PLC grew its position in shares of Cambrex by 14.4% in the 2nd quarter. Janus Henderson Group PLC now owns 475,862 shares of the biotechnology company’s stock worth $24,888,000 after buying an additional 60,046 shares during the period. Northpointe Capital LLC purchased a new stake in shares of Cambrex in the 3rd quarter worth about $2,404,000. Summit Creek Advisors LLC grew its position in shares of Cambrex by 52.7% in the 3rd quarter. Summit Creek Advisors LLC now owns 235,521 shares of the biotechnology company’s stock worth $16,110,000 after buying an additional 81,290 shares during the period. Rhumbline Advisers grew its position in shares of Cambrex by 5.5% in the 2nd quarter. Rhumbline Advisers now owns 81,500 shares of the biotechnology company’s stock worth $4,262,000 after buying an additional 4,250 shares during the period. Finally, CWM LLC purchased a new stake in shares of Cambrex in the 3rd quarter worth about $2,360,000.
Shares of Cambrex stock opened at $47.83 on Monday. The stock has a market capitalization of $1.61 billion, a P/E ratio of 15.09, a PEG ratio of 1.73 and a beta of 2.36. Cambrex Co. has a 1 year low of $44.92 and a 1 year high of $69.43. The company has a current ratio of 4.54, a quick ratio of 3.41 and a debt-to-equity ratio of 0.49.
Cambrex (NYSE:CBM) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.59 by ($0.10). The firm had revenue of $104.62 million during the quarter, compared to the consensus estimate of $122.04 million. Cambrex had a return on equity of 22.20% and a net margin of 22.67%. The business’s revenue for the quarter was down 7.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.55 EPS. As a group, analysts expect that Cambrex Co. will post 2.77 earnings per share for the current fiscal year.
A number of research firms have recently weighed in on CBM. Zacks Investment Research raised shares of Cambrex from a “hold” rating to a “strong-buy” rating and set a $73.00 target price on the stock in a research report on Wednesday, August 8th. Robert W. Baird assumed coverage on shares of Cambrex in a research note on Thursday, November 15th. They issued an “outperform” rating on the stock. Jefferies Financial Group assumed coverage on shares of Cambrex in a research note on Tuesday, September 25th. They issued a “buy” rating and a $75.50 price target on the stock. Finally, First Analysis upgraded shares of Cambrex from an “outperform” rating to a “strong-buy” rating and dropped their price target for the stock from $73.00 to $63.00 in a research note on Friday, November 9th. Two research analysts have rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $70.50.
In other Cambrex news, CEO Steven M. Klosk sold 20,000 shares of the company’s stock in a transaction dated Tuesday, October 23rd. The shares were sold at an average price of $54.76, for a total transaction of $1,095,200.00. Following the transaction, the chief executive officer now owns 103,328 shares in the company, valued at approximately $5,658,241.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Steven M. Klosk sold 55,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $66.30, for a total transaction of $3,646,500.00. Following the transaction, the chief executive officer now owns 138,328 shares in the company, valued at approximately $9,171,146.40. The disclosure for this sale can be found here. Insiders own 2.42% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “30,038 Shares in Cambrex Co. (CBM) Purchased by Cardan Capital Partners LLC” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/12/03/30038-shares-in-cambrex-co-cbm-purchased-by-cardan-capital-partners-llc.html.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Read More: Conference Calls
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.